sepsis in the rural setting: early recognition and management
DESCRIPTION
Sepsis in the Rural Setting: Early Recognition and Management . Mike Broyles, BSPharm, PD, PharmD Director of Pharmacy and Laboratory Services Five Rivers Medical Center Pocahontas, AR . No Disclosures. Objectives. Outline. Severe sepsis is costly and life-threatening. - PowerPoint PPT PresentationTRANSCRIPT
Sepsis in the Rural Setting: Early Recognition and Management
Mike Broyles, BSPharm, PD, PharmDDirector of Pharmacy and Laboratory ServicesFive Rivers Medical CenterPocahontas, AR
No Disclosures
ObjectivesUnderstand the definitions and differing clinical presentations of SIRS, Sepsis, Severe Sepsis and Septic shock as defined by SCCM/ACCP
Discuss the role of biomarkers, clinical presentation, and other laboratory tests used in the evaluation of patients with suspected Sepsis
Recognize how procalcitonin, other biomarkers, and clinical exam can assist in early recognition, risk stratification, and management of patients with suspected and confirmed Sepsis
Outline
Seriousness of sepsis
Difficulties with the
diagnosis of sepsis
Procalcitonin (PCT)• Biomarker• Kinetics
Comparison to other
biomarkers
Application of PCT into
sepsis managemen
t
• Strikes more than 750,000 people each year in the United States
• Mortality remains greater than 30% (1 person every 2.5 minutes)
• Mortality rate has not improved in the last 20 years• Newborn, pediatric, adults, aged• Morbidity• Surgical sepsis rate is increasing
• Clinical diagnosis remains challenging
Severe sepsis is costly and life-threatening
Determinants of mortality from sepsis
• Early intervention is critical• Appropriate antibiotic therapy within
one hour of hypotension• Resuscitation / re-establish perfusion
within six hours
Duration of hypotension before initiation of appropriate ABX therapy is the critical determinant of survival in septic shock
Why do we struggle with the diagnosis of sepsis?
Relationship of SIRS, Sepsis, and Infection
SIRS Criteria: Two or more of the following
• Temperature > 100.4F (38C) or < 96.8F (36C)• Heart rate > 90 beats/minute• Respiratory rate > 20 breaths/minute or
PaCO2 < 32 mm Hg• WBC
o > 12,000/mm3 o < 4000/mm3 o > 10% immature (band) forms
• Tachycardia – 718 possibilities• Tachypnea - 371 possibilities • Increased/Decreased Temperature – 1380
possibilities• Increased/Decreased WBC – 350
possibilities
Making the Diagnosis
www.diagnosispro.com
541 possible diagnoses with 2 or more of the criteria
Sepsis: ACCP/SCCM Definitions•Sepsis is SIRS plus a known or suspected infection.•Severe Sepsis is sepsis associated with organ dysfunction, hypoperfusion, or hypotension.• Septic Shock is sepsis-induced hypotension despite adequate
fluid resuscitation along with the presence of perfusion abnormalities.
• May include• Lactic acidosis• Oliguria• An Acute alteration in mental status• Others…
Bone RC, et al. Chest 1992 Jun;101(6):1644-55.
SIRSSepsis
Severe SepsisSeptic Shock
100% 100% 100%
0% 0% 0%Pretest situation: only clinical assessment is available
Assessment of individual features and addition of PCT
Post-test situation: Individually adjusted risk assessment
Probability of a Sepsis Diagnosis
40%
PCT 2.0
PCT 0.3
> 90%
< 10%
Michael Meisner; Procalcitonin-Biochemistry and Clinical Diagnosis
What is Procalcitonin and its role in sepsis management?
Procalcitonin• PCT is an immunologically active protein• PCT is induced in systemic inflammatory reactions • Bacterial infections induce PCT• PCT induction is generally in direction proportion to
the bacterial insult to the body• Viral infections, autoimmune diseases, transplant
rejections, and allergic reactions generally do not induce PCT
• PCT is therefore an “indirect marker” of a bacterial infection: PCT a measurement of the body’s inflammatory response to the bacteria
Calcitonin: Source of
production in healthy
people
Müller B. et al., JCEM 2001
In relevant bacterial infection, PCT is produced and released into circulation from the entire body
Highly specific induction – Produced all tissue
Healthy Sepsis
PCT:Source of Productionin Septic Patients
PCT Kinetics
• Rapid kinetics: detectable 3 hours after infection has begun, with a peak after 12 to 24 hours
• Peak values up to 1000 ng/ml• Half-life: ~ to 24 hours
17Brunkhort FM et al., Intens. Care Med (1998) 24: 888-892
Time (Hours)
Plas
ma
Conc
entr
ation
1 2 6 12 24 48 72
PCT
• In critically ill patients, PCT levels elevate in correlation to the severity of bacterial infection
• Integrating PCT in sepsis management can lead to improved patient outcomes
PCT values correlate directly with severity of bacterial load
Healthy Individuals
Local Infections
Systemic Infections (Sepsis)
Severe Sepsis
Septic Shock
0.05 ng/ml
0.5 ng/ml
2 ng/ml
PCT as a response to bacterial challenge
Elevated or rising PCT values• Systemic response to bacterial infection
oProgressing infectiono Immune system is overwhelmed
• Risk of significant disease progression
Low PCT values in presence of clinical presentation• Self-limiting infection• Non-bacterial etiology• Early phase of infection
• Primary inflammation syndrome following trauma: multiple trauma, extensive burns, major surgery (abdominal and transplant)
• Severe pancreatitis or severe liver damage (1)• Prolonged circulatory failure: IE severe multiple organ
dysfunction syndrome (MODS) (1.4)• Medullary C-cell cancers of the thyroid, pulmonary small-
cell carcinoma and bronchial carcinoma• Newborn < 48hr - increased PCT values (physiological
peak)
Procalcitonin release in the absence of infection
Newborns less than 48 hours PCT measurements
Age (hours) PCT (ng/ml)0 – 6 hours ≤ 2
6 – 12 hours ≤ 812 – 18 hours ≤1518 – 30 hours ≤ 2130 – 36 hours ≤ 1536 – 42 hours ≤ 842 – 48 hours ≤ 2
Chiesa et al., Council & Institute of Ped (1998) 45: 89-97
C-Reactive Protein (CRP)• Acute Phase Reactant synthesized by
the liver• Secretion triggered by cytokine (IL-6, IL-1, TNF-
α)
• Produced in response to acute & chronic inflammation • Bacterial, Viral, Fungal• Rheumatic• Inflammatory diseases• Malignancy• Tissue Injury, Necrosis• Steroid Treatment• Liver Failure• Obesity
• Advantages: o Rises in 4 to 6 hours
• Disadvantages: o Non-specifico No correlation to SOFA Scores, o Slow Kinetics (peak 36-50h)
Vingishi et al., J Clin Invest. 1993 Apr ; 91(4): 1351-7Pepys et al., J of Clin Invest. 2003g 1807 col 2 para 2, pg 1808 col 1 para 1Standage et al., Expert Rev Anti Infect Ther. 2011 Jan 9(1): 71-79
Interleukin-6 (IL-6)• Pro-inflammatory cytokine (messenger protein)• Blood, monocytes, and endothelial cells• Advantage
o Quick rise – one houro Decreases rapidly
• Disadvantageo Any inflammatory process can increase IL-6o Affected in immune-compromised patientso Sample must be cooled and spun immediatelyo Containers must be free of endotoxins since IL-6 can be formed by
decomposed leukocytes in the blood sample
Vingishi et al., J Clin Invest. 1993 Apr ; 91(4): 1351-7Pepys et al., J of Clin Invest. 2003g 1807 col 2 para 2, pg 1808 col 1 para 1Standage et al., Expert Rev Anti Infect Ther. 2011 Jan 9(1): 71-79
LactateLactate (lactic acid) is produced due to inadequate tissue perfusion – a defining parameter of late sepsis.• Advantage
• Rapid turn-around• Readily available• Reliable marker of perfusion and prognosis
• Disadvantage• Late elevation in course of sepsis• Non-specific
Reduction of lactate is advocated as a target for therapeutic interventions (2C)
Blomkalns AL www.emcreg.org 2007Poeze M, et al. Crit Care Med 2005 Nov;33(11):2494-500Muller B, et al. Crit Care Med 2000 Apr;28(4):977-83
Diagnostic accuracy of PCT compared to other biomarkers used in sepsis
Day 1
@ ...
Day 2
@ ...
Day 2
@ ...
Day 2
@ ...0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
5
0.05 0.05 0.05
2.7
4.3
1.51
PCT LactateTro-ponin
BP 142/82 90/58 98/60
“BE”: UTI Case: Lactate Specificity
ABX Ceftriaxone Zosyn-Tobramycin Vancomycin
Case PresentationsApplication of PCT use for Sepsis and Antibiotic Management
HW
CC/Hx/
Presentation
73 Y/O femaleCC: dysuria, mental status changes, fever, nausea/vomitingS/P laparoscopic cholecystectomy: 4 days post procedural complication r/oTemp 103.4RR 19BP 86/52HR 95WBC 28.4 w/4 bandsSrCr 1.6 w/ BUN 38Mini-cath UA• Nitr
ite positive
• 4+ bacteria
Medications
Amlodipine 10mg dailyBenazepril 20mg dailyPropranolol LA 160mg dailyHCTZ 25mg dailyAspirin 81 mg dailyFurosemide 40mg prn daily for leg edemaOxybutynin 5mg bid Alprazolam 0.5mg tid Dicyclomine 10mg prn tid for irritable bowelMeloxicam 15mg dailyZolpidem 5mg hs
HW
ED Treatment Plan: Dx of Sepsis due to UTI
• Admit to ICU • Meropenem • Tobramycin• Cystalloids and dopamine
HW• Hospitalist orders PCT in ICU after admission• PCT 0.25 ng/ml • Fluid bolus and continued rehydration• DC dopamine• DC merpenem• DC tobramycin• Start piperacillin/tazobactam • Moved to Med-Surg• Cx: Proteus mirabilis sensitive to 1st generation
cephalosporins and resistant to quinolones (day2)• Changed to cephalexin
HW Clinical Perles• Patient met SIRS criteria• SIRS criteria complicated by medications?• SIRS criteria clouded by volume depletion?• Baseline PCT • Process to ensure PCT draw• Establish a process - Order sets
Considerations
• Assumed sepsis prompting aggressive response• ICU admission?• Vasopressor?
Labs/X-
Ray/Plan
Temp 99.2Pulse 80-90WBC 13.1SrCr 2.1PCT 21Plain FilmUS: Subcutaneous edema suggesting cellulitis, but no localized collectionsMRI: Myositis involving vastus lateralis muscle with overlying cellulitis. Most likely etiologies from infection or traumaSurgery consultAntibiotics
CC/Hx/
Presentation
48 Y/O maleOccupation: LinemanCC: Worsening right thigh and knee painFive scratches on leg, 2 -3 cm in length from thorns/briarsPain is not proportional to visual presentationStarted 24 hours agoComplains area is “pulsing”Patient states: “Some swelling in last 18 hours”
WR
WR
ED orders
• Clindamycin 300 IV once • Doxycycline 100 mg IV once
Initial Admission orders
• Clindamycin 300 mg IV every 6 hours• Doxycycline 100 mg IV every 12 hours
WR
Revised admission orders
• DC Doxycycline• Clindamycin 800 mg IV every 8 hours• Piperacillin/tazobactam 3.375 grams IV
every 6 hours
WR
ED @ 1130 Day 1 @ 0800 Day 1 @ 12000
1
2
3
4
5
6
Lactic Acid
ED @ 1130 Day 1 @ 0530 Day 1 @ 0800 Day 1 @ 12000
100
200
300
400
500
600
PCT
ED @ 1120 Day 1 @ 0530 Day 1 @ 08000
2
4
6
8
10
12
14
16
WBC
ED @ 1130 Day 1 @ 0530 Day 1 @ 12000
1
2
3
4
5
6
7
SrCr
WR – MRI Leg
WR – MRI Leg
WR Clinical Perles: Continued Procalcitonin escalation despite suspected adequate Abx
• Clinical presentation mismatch to seriousness of illness
• A significant elevation in PCT is always a cause for concern
• Resistant organism• Abscess• Need for surgical intervention • Other source/site of infection
STMedications
Glargine insulin 32 units dailyRegular insulin Sliding ScaleSitagliptin 100mg dailyLisinopril 20mg bidFurosemide 20mg bidCarvedilol 25mg bid Gabapentin 400mg tidPregabalin 150mg bid Alprazolam 0.5mg prn tid“Aleve” 440mg prn bid on “most days” Hydrocodone/Acet 5mg/325mg prn q 4h for pain
CC/Hx/
Presentation
66 Y/O female CC: pain, tenderness, and fever with recurrent cellulitis of left great toe and shin just superior to ankleSecond day of recurrent infection that had “resolved” two weeks agoAdult onset insulin dependent diabeticNeuropathy in legs/feetMild CHFHTN
ST clinical course
Admission – AM
• Plain film • Scheduled MRI• WBC 12.8• PCT 0.6• SrCr 1.8• Piperacillin/Tazobactam • Vancomycin
ST clinical course
Day 1 - AM
• WBC 14.4• PCT 16• Lactate 2.1• SrCr 1.7• Replace Piperacillin/Tazobactam with Meropenem
Day 1 - PM
• WBC 16.8• PCT 26• Lactate 2.1• Replaced Vancomycin with Linezolid
ST clinical course
Day 2 - AM
• WBC 24.8• PCT 77• Lactate 4.4 • SrCr 2.4• Worsened hemo-dynamically: increased LVP rate• Added Tobramycin 7mg/kg
Day 2 - PM
• PCT 64• Lactate 2.2
ST clinical course
Day 3 - AM
• WBC 22.0• PCT 39• Lactate 1.9• Blood Cx: gram stain gram negative rods
Day 3 - PM
• First blood Cx and sensitivity completed• Escherichia coli: CRE
Culture Report Organism 01 Escherichia coli (esccol) Antibiotics Ampicillin RAmpicillin/Sulbactam RCeftizoxime RGentamicin RESBL POSCefoxitin RCeftazidime RCeftriaxone RCefepime RImipenem RMeropenem RAmikacin STobramycin SPiperacillin/Tazobactam RLevofloxacin RTrimethoprim/Sulfamethox R
ST Blood Culture #1
Ad-mis-sion
Day 1 AM
Day 1 PM
Day 2 AM
Day 3 AM
Day 4 AM
Day 5 AM
0
5
10
15
20
25
30
WBC
Ad-mis-sion
Day 1 AM
Day 1 PM
Day 2 AM
Day 2 PM
Day 3 AM
Day 4 AM
Day 5 AM
0102030405060708090
PCT
Ad-mis-sion
Day 1 AM
Day 2 AM
Day 3 AM
Day 4 AM
Day 5 AM
0
0.5
1
1.5
2
2.5
3SrCr
Day 1 PM Day 2 AM Day 2 PM Day 3 AM Day 4 AM Day 5 AM0
0.51
1.52
2.53
3.54
4.55
Lactic Acid
ST Clinical Perles
• Understanding PCT principles will allow effective monitoring and shorten time to intervene > requires through education efforts
• Reducing intervention time can preempt more serious disease progression
• PCT is effective in monitoring and managing antibiotic therapy
GMCC/Hx83 Y/O
femaleNursing home residentCC: SOBWorsening over 4 daysCOPD (Gold Stage III)Recent pneumonia hospitalizationCHFHTNFibromyalgiaGERDAAA Repair2 stents in 2012Spine surgery X4
Presentation
Pulse Ox 82%RR 24Prolonged expirationRhonchi bilaterally A/PChest filmWBC 3.2Platelets 99,000PCT 0.06Temp 102.4BP 143/87Pulse 77BNP 489
GMMedications
Ticagrelor 90mg bidAspirin 81mg daily (was 325mg)Pregabalin 75mg bidCarvedilol 6.25mg bid Atorvastatin 40mg dailyAmiodarone 100mg dailyEnalapril 20mg bid Mirtazapine 15mg hsFurosemide 40mg daily (doubled last 4 days)Hydrocodone/APAP 10mg qid Duloxetine 60mg dailyIpratropium/Albuterol qidAlbuterol prn q 2 hours“Prednisone taper”
Assessment/
Plan
Pneumonia• Infilt
rates
• Productive cough
• Signs of infection/inflammation
COPD exacerbationCHF exacerbationCefepimeVancomycinMethylpresnisoloneFurosemidePeripheral smear
GM
Admission
• Cefepime 1gm q 8 hours• Vancomycin dose adjusted• Furosemide 40mg IV q 12 hours• Methylprednisolone 60mg IV q 6 hours
Day 1 AM
• All meds same except:• DC Furosemide: BP 90/60’s & HR > 110
Admit Day 1 Day 2 Day 3 Day 4 Day 5 Day 6
Methylprednisolone60mg q 6h 60mg q 6h 40mg q 6h 40mg q 8h 40mg q 8h 40mg q12h 40mg daily
Admission Day 1 Day 2 Day 3 Day 4 Day 5 Day 60
5
10
15
20
25
30
3.2
18.122.8
28.224.6
16.3
10.8
WBC
Admission Day 1 Day 2 Day 3 Day 4 Day 5 Day 60
2
4
6
8
10
12
14
5.6
12.8
5.9
3.1
1.40.8 0.4
PCT
Admission Day 1 Day 2 Day 3 Day 4 Day 5 Day 60
2
4
6
8
10
12
14
5.6
12.8
5.9
3.1
1.40.8 0.4
PCT
Admission Day 1 Day 2 Day 3 Day 4 Day 5 Day 60
1
2
3
4
5
6
2
5.7
2
0.5
Lactate
Admission Day 1 Day 2 Day 3 Day 4 Day 5 Day 60
5
10
15
20
25
30
3.2
18.1
22.8
28.2
24.6
16.3
10.8
WBC
GM Clinical Perles
• WBC may be a poor biomarker affected by immune state, diseases, and steroids
• When LOS permits, use PCT follow up algorithms to stop antibiotic therapy sooner
• Decrease ABX exposure• Selection for resistance• Adverse event reduction
Keys to Success: Early Recognition and Treatment
• Process in place to avoid loopholes and achieve consistency
• Protocol or Order Sets• Appropriate biomarkers with clinical presentation
o Sensitivityo Specificity
• Lactate should be used primarily for evaluation of resuscitation efforts
• Educate staff
Five Rivers Medical Center
Outcomes Comparison: Control Vs. ProcalcitoninDate range 3 yearsCase Mix: 40% coded to an ID related diagnosisSepsis related LOS -50%Sepsis related drugs costs -50%ICU admissions due to sepsis -64%Antibiotic exposure – sepsis related -45%GI related ADR’s (all reported) -40%Clostridium difficile infections -54%
The most important indications for PCT levels• Diagnosis of sepsis, severe sepsis, and septic shock• Differential diagnosis of clinically relevant bacterial
infections and sepsis• Evaluation of the severity of a bacterial infection and
systemic inflammatory reactions• Monitoring of the course of treatment of patients with
sepsis• Evaluation of progression and control of antibiotic
treatment
Summary
Michael Meisner; Procalcitonin-Biochemistry and Clinical Diagnosis
Questions